TOKYO and CAMBRIDGE, Mass., Jan 6, 2026 - (JCN Newswire via SeaPRwire.com) - Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, “Biogen”) announced today that the Biologics License Application (BLA) for the subcutaneous formulation (subcutaneous autoinjector: SC-AI) of “LEQEMBI®” (generic name: lecanemab), an anti-amyloid beta (Aβ) protofibril antibody, has been accepted by the National Medical Products Administration (NMPA) in China. If approved, the SC-AI of 500 mg (two 250 mg injections) could be used to administer a once-weekly dose at home from the initiation of treatment, as an alternative to the current IV administration every two weeks in a hospital setting. The potential approval of SC-AI would expand the option for patients and care partners to receive LEQEMBI treatment at home. The injection time for each autoinjector (250mg injection) is approximately 15 seconds. The SC formulation also has the potential to reduce healthcare resources associated with IV dosing, such as preparation for infusion and nurse monitoring, while streamlining the overall AD treatment care pathway.Eisai estimates that there were 17 million patients with MCI or mild dementia due to AD in China in 2024, which is expected to increase with the aging of the population.Eisai serves as the lead of LEQEMBI development and regulatory submissions globally with Eisai and Biogen co-commercializing and co-promoting the product and Eisai having final decision-making authority. Eisai will distribute the product in China and will conduct information provision activities through specialized Medical Representatives.*Protofibrils are believed to contribute to the brain injury that occurs with AD and are considered to be the most toxic form of Aβ, having a primary role in the cognitive decline associated with this progressive, debilitating condition.(1) Protofibrils cause injury to neurons in the brain, which in turn, can negatively impact cognitive function via multiple mechanisms, not only increasing the development of insoluble Aβ plaques but also increasing direct damage to brain cell membranes and the connections that transmit signals between nerve cells or nerve cells and other cells. It is believed the reduction of protofibrils may prevent the progression of AD by reducing damage to neurons in the brain and cognitive dysfunction.(2) MEDIA CONTACTSEisai Co., Ltd.Public Relations DepartmentTEL: +81 (0)3-3817-5120Eisai Europe, Ltd.EMEA Communications Department+44 (0) 797 487 9419Emea-comms@eisai.netEisai Inc. (U.S.)Libby Holman+1-201-753-1945Libby_Holman@Eisai.comBiogen Inc.Madeleine Shin+1-781-464-3260public.affairs@biogen.comINVESTOR CONTACTSEisai Co., Ltd.Investor Relations DepartmentTEL: +81 (0) 3-3817-5122Biogen Inc.Tim Power+ 1-781-464-2442IR@biogen.comAbout LEQEMBI (generic name: lecanemab)Lecanemab is the result of a strategic research alliance between Eisai and BioArctic. It is a humanized immunoglobulin gamma (IgG1) monoclonal antibody directed against aggregated soluble (protofibril) and insoluble forms of amyloid-beta (Aβ). Lecanemab has been approved in 52 countries and is under regulatory review in 8 countries. Following the initial phase with treatment every two weeks for 18 months, intravenous (IV) maintenance dosing with treatment every four weeks was approved in the U.S., China, the UK, and others, and applications have been filed in 4 countries and regions. The U.S. FDA approved Eisai’s Biologics License Application (BLA) for subcutaneous maintenance dosing with LEQEMBI IQLIK in August 2025. A rolling Supplemental Biologics License Application (sBLA) for initiation treatment was initiated under Fast Track status in September 2025, and completed in November 2025. In November 2025, an application for a subcutaneous injectable formulation in Japan was submitted. In December 2025, Lecanemab has been included in the “Commercial Insurance Innovative Drug List”, recently introduced by the National Healthcare Security Administration (NHSA) of China.Since July 2020 the Phase 3 clinical study (AHEAD 3-45) for individuals with preclinical AD, meaning they are clinically normal and have intermediate or elevated levels of amyloid in their brains, is ongoing. AHEAD 3-45 is conducted as a public-private partnership between the Alzheimer's Clinical Trial Consortium that provides the infrastructure for academic clinical trials in AD and related dementias in the U.S, funded by the National Institute on Aging, part of the National Institutes of Health, Eisai and Biogen. Since January 2022, the Tau NexGen clinical study for Dominantly Inherited AD (DIAD), that is conducted by Dominantly Inherited Alzheimer Network Trials Unit (DIAN-TU), led by Washington University School of Medicine in St. Louis, is ongoing and includes lecanemab as the backbone anti-amyloid therapy.About the Collaboration between Eisai and Biogen for ADEisai and Biogen have been collaborating on the joint development and commercialization of AD treatments since 2014. Eisai serves as the lead of lecanemab development and regulatory submissions globally with both companies co-commercializing and co-promoting the product and Eisai having final decision-making authority.About the Collaboration between Eisai and BioArctic for ADSince 2005, Eisai and BioArctic have had a long-term collaboration regarding the development and commercialization of AD treatments. Eisai obtained the global rights to study, develop, manufacture and market lecanemab for the treatment of AD pursuant to an agreement with BioArctic in December 2007. The development and commercialization agreement on the antibody lecanemab back-up was signed in May 2015.About Eisai Co., Ltd.Eisai's Corporate Concept is "to give first thought to patients and people in the daily living domain, and to increase the benefits that health care provides." Under this Concept (also known as human health care (hhc) Concept), we aim to effectively achieve social good in the form of relieving anxiety over health and reducing health disparities. With a global network of R&D facilities, manufacturing sites and marketing subsidiaries, we strive to create and deliver innovative products to target diseases with high unmet medical needs, with a particular focus in our strategic areas of Neurology and Oncology.In addition, we demonstrate our commitment to the elimination of neglected tropical diseases(NTDs), which is a target (3.3) of the United Nations Sustainable Development Goals (SDGs), by working on various activities together with global partners.For more information about Eisai, please visit www.eisai.com (for global headquarters: Eisai Co.,Ltd.), and connect with us on X, LinkedIn and Facebook. The website and social media channels are intended for audiences outside of the UK and Europe. For audiences based in the UK and Europe, please visit www.eisai.eu and Eisai EMEA LinkedIn.About BiogenFounded in 1978, Biogen is a leading biotechnology company that pioneers innovative science to deliver new medicines to transform patient’s lives and to create value for shareholders and our communities. We apply deep understanding of human biology and leverage different modalities to advance first-in-class treatments or therapies that deliver superior outcomes. Our approach is to take bold risks, balanced with return on investment to deliver long-term growth.The company routinely posts information that may be important to investors on its website at www.biogen.com. Follow Biogen on social media – Facebook, LinkedIn, X, YouTube.For more details, please visit: https://www.eisai.com/news/2026/pdf/enews202601pdf.pdf Copyright 2026 JCN Newswire via SeaPRwire.com. All rights reserved. www.jcnnewswire.com
香港, 2026年1月6日 - (亚太商讯 via SeaPRwire.com) - 2026年1月5 日, 由黑桃资本有限公司（「黑桃资本」）之附属公司发起的特殊目的收购公司（「SPAC」）Black Spade Acquisition III Co（「本公司」），今天宣布其首次公开发行的15,000,000 单位价格为每单位10.00 美元。这些单位预计将于 2026 年 1 月 6 日在纽约证交所（「纽交所」）上市交易，股票代号为「BIIIU」。每个单位由一股A 类普通股和三分之一的可赎回认股权证组成。受限于若干调整，每一完整认股权证均可以每股11.50 美元的行使价格购买一股A 类普通股。单位分拆后不会发行零碎认股权证，只有完整认股权证方可进行交易。当构成这些单位的证券开始单独交易时，A类普通股和认股权证预计将在纽交所上市，股票代号分别为「BIII」和「BIIIW」。根据惯例交易条件，此次发行预计将于 2026 年 1 月7日完成。本公司已授予承销商为期 45 天的选择权，允许其以首次公开发行价格减去承销折扣和佣金后的价格，额外购买额外2,250,000 份单位，以弥补任何超额配售。本公司的管理团队由执行主席兼联席行政总裁谭志伟先生、联席行政总裁兼首席财务官吴绳祖先生以及联席行政总裁兼首席营运官Richard Taylor先生带领。彼等各曾担任Black Spade Acquisition Co（「 BSAQ」） 及Black Spade Acquisition II Co（「 BSII」）的执行董事或顾问。BSAQ及BSII亦是由黑桃资本之附属公司发起的特殊目的收购公司。于2023年8月，BSAQ与越南领先汽车制造商VinFast完成了价值230亿美元的企业合并，为当时有史以来以交易作价计算第三大的特殊目的收购公司企业合并（「 de-SPAC」）。于2025年6月，即少于BSII上市后10个月，BSII与The Generation Essentials Group完成了价值4.88亿美元的企业合并。执行主席兼联席行政总裁谭志伟先生表示: 「我们非常高兴能够透过推出 Black Spade Acquisition III Co 作为 2026 年首批 IPO 之一来扩展我们的特殊目的收购公司系列。 黑桃在生活品味及娱乐领域的强大背景以及自身商业网络和专业知识，构成了我们第三个特殊目的收购公司的基石。」Cohen & Company Capital Markets（Cohen & Company Securities, LLC的分部）和Chardan担任该交易的联合账簿管理人。此次公开发行仅透过招股章程方式进行。招股章程副本可向 Cohen & Company Capital Markets（Cohen & Company Securities, LLC的分部）（收件人：Prospectus Department, 3 Columbus Circle, 24th Floor, New York, NY 10019，或透过电子邮件 capitalmarkets@cohencm.com）、Chardan （收件人：One Pennsylvania Plaza, Suite 4800, New York, NY 10019，或透过电子邮件 prospectus@chardan.com）或从 SEC 网站 www.sec.gov取得。与证券相关的登记声明已向美国证券交易委员会（「SEC」）提交，并于 2026 年 1 月5日生效。本新闻稿不构成出售要约或购买要约邀请。如根据任何州份或司法管辖区的证券法，在注册或取得资格之前此类要约、邀请或出售属于非法行为，也不得在该州或司法管辖区出售这些证券图片说明：(左起) 联席行政总裁兼首席营运官Richard Taylor先生、执行主席兼联席行政总裁谭志伟先生、黑桃资本有限公司创办人何猷龙先生、联席行政总裁兼首席财务官吴绳祖先生关于 Black Spade Acquisition III CoBlack Spade Acquisition III Co 是其创办人黑桃资本之附属公司所成立的第三个SPAC，旨在与一项或多项业务或资产进行合并、股份交换、资产收购、股份购买、重组或类似业务合并。尽管本公司可能会在任何行业寻求业务合并，但它仍视生活品味及娱乐领域为其核心重点领域之一。本公司尤其对该领域的用户体验如何被人工智能、机器人和量子计算的应用而提升感到特别鼓舞。本公司期待进一步探索数字资产在休闲娱乐产业中日益被接受所带来的机遇。Forward-Looking StatementsThis press release contains statements that constitute "forward-looking statements," including with respect to the proposed initial public offering, the anticipated use of the net proceeds, and the search for an initial business combination. No assurance can be given that the offering discussed above will be completed on the terms described, or at all, or that the net proceeds of the offering will be used as indicated.Forward-looking statements are subject to numerous conditions, many of which are beyond the control of the Company, including those set forth in the Risk Factors section of the Company's registration statement and preliminary prospectus for the Company's initial public offering filed with the SEC. Copies of these documents are available on the SEC's website, www.sec.gov. The Company undertakes no obligation to update these statements for revisions or changes after the date of this release, except as required by law.投资者关系查询：ir@bsaiii.com Copyright 2026 亚太商讯 via SeaPRwire.com. All rights reserved. www.acnnewswire.com
